SPbSRIVS launches clinical trials of COVID-19 vaccine

20 July 2021
On July 19, 2021, the Russian Ministry of Health granted the Saint Petersburg Institute of Vaccines and Serums official approval to conduct Phase I and Phase II clinical trials of a sub-unit recombinant vaccine for the prevention of the new coronavirus infection caused by SARS-CoV-2. Adults aged between 18 and 60 years will take part in the trial.

In June 2021, preclinical trials of the vaccine formulation were successfully completed, proving its safety, immunogenicity, and protectivity (protective capacity).

The vaccine is designed on a cutting-edge technology platform and is aimed primarily at developing cellular immunity, using as a target the conservative virus proteins that are least susceptible to mutations.